PubRank

T1DM Immunotherapy Using Polyclonal Tregs + IL-2 (TILT)

Clinical Trial ID NCT02772679

PubWeight™ 0.00‹?›

🔗 Visit the ClinicalTrials.gov page for NCT02772679

Top papers

Rank Title Journal Year PubWeight™‹?›
1 In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med 2004 8.00
2 The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat Immunol 2008 6.56
3 Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity 2008 6.08
4 Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol 2001 4.99
5 C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 2009 4.13
6 IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood 2005 4.06
7 Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases. Nat Rev Immunol 2010 3.69
8 Distinct roles of CTLA-4 and TGF-beta in CD4+CD25+ regulatory T cell function. Eur J Immunol 2004 3.18
9 CD3-specific antibodies: a portal to the treatment of autoimmunity. Nat Rev Immunol 2007 3.06
10 Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry. Diabetes Care 2015 2.79
11 Expansion of human regulatory T-cells from patients with type 1 diabetes. Diabetes 2008 2.52
12 Self-antigen-driven activation induces instability of regulatory T cells during an inflammatory autoimmune response. Immunity 2013 2.41
13 IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells. J Exp Med 2010 2.21
14 Type 1 diabetes immunotherapy using polyclonal regulatory T cells. Sci Transl Med 2015 2.13
15 Regulatory T-cell physiology and application to treat autoimmunity. Immunol Rev 2006 2.13
16 Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2013 1.92
17 Regulatory T-cell therapy: is it ready for the clinic? Nat Rev Immunol 2005 1.76
18 Expansion of regulatory T cells via IL-2/anti-IL-2 mAb complexes suppresses experimental myasthenia. Eur J Immunol 2010 1.72
19 Regulatory T cells control NK cells in an insulitic lesion by depriving them of IL-2. J Exp Med 2013 1.53
20 Administration of CD4+CD25highCD127- regulatory T cells preserves β-cell function in type 1 diabetes in children. Diabetes Care 2012 1.52
21 Effects of low-dose recombinant interleukin 2 to promote T-regulatory cells in alopecia areata. JAMA Dermatol 2014 1.51
22 Type 1 diabetes-associated IL2RA variation lowers IL-2 signaling and contributes to diminished CD4+CD25+ regulatory T cell function. J Immunol 2012 1.31
23 Therapy of type 1 diabetes with CD4(+)CD25(high)CD127-regulatory T cells prolongs survival of pancreatic islets - results of one year follow-up. Clin Immunol 2014 1.20
24 Soluble factors secreted by T cells promote β-cell proliferation. Diabetes 2013 1.14
25 Interleukin-2: clinical applications. Semin Oncol 2002 1.11
26 Rationale and study design of the Adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes (DILT1D): a non-randomised, open label, adaptive dose finding trial. BMJ Open 2014 1.01
27 Measurement of proliferation and disappearance of rapid turnover cell populations in human studies using deuterium-labeled glucose. Nat Protoc 2009 0.95
28 The IL-2/IL-2R system: from basic science to therapeutic applications to enhance immune regulation. Immunol Res 2013 0.94
29 Sustained stimulation and expansion of Tregs by IL2 control autoimmunity without impairing immune responses to infection, vaccination and cancer. Clin Immunol 2014 0.91
30 Differentiation, expansion, and homeostasis of autoreactive T cells in type 1 diabetes mellitus. Curr Diab Rep 2009 0.89
31 β-cell-specific IL-2 therapy increases islet Foxp3+Treg and suppresses type 1 diabetes in NOD mice. Diabetes 2013 0.83
32 Lymphopenia is detrimental to therapeutic approaches to type 1 diabetes using regulatory T cells. Immunol Res 2014 0.79
33 IL-2 immunotherapy reveals potential for innate beta cell regeneration in the non-obese diabetic mouse model of autoimmune diabetes. PLoS One 2013 0.78
34 Low-dose IL-2 as a therapeutic agent for tolerance induction. Immunotherapy 2011 0.78
Next 100